Jaguar's diarrhoea drug shows benefit in Phase III breast cancer subgroup [Yahoo! Finance]
Jaguar Health, Inc. (JAGX)
US:NASDAQ Investor Relations:
jaguarhealth.gcs-web.com/investor-overview
Company Research
Source: Yahoo! Finance
trial has shown statistically significant benefit in a prespecified subgroup of breast cancer patients. In July 2024, Jaguar announced the Phase III OnTarget trial (NCT04538625), conducted by Jaguar family company Napo Pharmaceuticals, evaluating crofelemer failed to meet the primary endpoint of frequency of diarrhoea across all tumour types. At the time, the company said the drug did reveal clinically relevant signals in prespecified subgroups that comprise patients with breast and respiratory cancer, including lung cancer. After the July announcement, shares in the Nasdaq-listed company opened 66% lower compared to a pre-announcement market close. In an announcement yesterday (1 October), Jaguar revealed a prespecified subgroup of adult patients with breast cancer dosed with crofelemer achieved statistical significance in the primary endpoint. Jaguar said the drug has the potential to help breast cancer patients to better adhere to their cancer therapies. Despite the positiv
Show less
Read more
Impact Snapshot
Event Time:
JAGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAGX alerts
High impacting Jaguar Health, Inc. news events
Weekly update
A roundup of the hottest topics
JAGX
News
- Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe” [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”Accesswire
- Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Reports Third Quarter 2024 Financial ResultsAccesswire
JAGX
Sec Filings
- 11/13/24 - Form 424B5
- 11/13/24 - Form 8-K
- 11/13/24 - Form 10-Q
- JAGX's page on the SEC website